PLSE Stock Analysis: Pulse Biosciences | NASDAQ
Medical Instruments & Supplies | NASDAQ, USA | Market Cap: 3.756m USD | 12M Return: 209.2% | US74587B1017 | Charts, Fundamentals & Technical Analysis
Avg Turnover: 19.1M
Qual. Beats: -1
Qual. Beats: 0
Warnings
Tailwinds
Seasonality 10.4 years of data
How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, >40 gets interesting and >55 is strong.
Pulse Biosciences, Inc. (PLSE) is a U.S.-based bioelectric medicine company that develops and commercializes a proprietary Nanosecond Pulsed-Field Ablation (nsPFA) delivery platform marketed under the nPulse brand. Its product portfolio spans multiple clinical applications, including the treatment of benign skin lesions, soft tissue ablation in surgical settings, and cardiac applications targeting atrial fibrillation through both surgical clamps and catheter-based systems. All products are operated through the nPulse Console, a software-enabled platform designed to fit physician clinical workflows.
The company was founded in 2014 as Electroblate, Inc. and rebranded to Pulse Biosciences in December 2015, with its current headquarters in Miami, Florida. Within the Health Care Equipment sub-industry, Pulse Biosciences operates in the emerging field of pulsed-field ablation, a non-thermal technology that uses ultra-short electrical pulses to selectively target tissue, distinguishing it from conventional thermal ablation modalities such as radiofrequency or cryoablation.
- FDA approval timeline for nPulse Cardiac Catheter System
- Clinical trial data readouts for nsPFA cardiac ablation
- Competition intensifies from Boston Scientific and J&J in pulsed-field ablation
- Cash burn and capital raises dilute shareholders
| Net Income: -80.1m TTM > 0 and > 6% of Revenue |
| FCF/TA: -0.53 > 0.02 and ΔFCF/TA -15.92 > 1.0 |
| NWC/Revenue: 7.99k% < 20% (prev 3.97k%; Δ 4.02k% < -1%) |
| CFO/TA -0.53 > 3% & CFO -61.1m > Net Income -80.1m |
| Net Debt/EBITDA: error (EBITDA <= 0) |
| Current Ratio: 9.63 > 1.5 & < 3 |
| Outstanding Shares: last quarter (69.2m) vs 12m ago 2.86% < -2% |
| Gross Margin: -21.60% > 18% (prev 33.93%; Δ -55.54% > 0.5%) |
| Asset Turnover: 1.01% > 50% (prev 2.08%; Δ -1.07% > 0%) |
| Interest Coverage Ratio: error (cannot be calculated; needs correct EBIT TTM and Interest Expense TTM) |
| A: 0.82 (Total Current Assets 105.7m - Total Current Liabilities 11.0m) / Total Assets 115.6m |
| B: -4.38 (Retained Earnings -506.5m / Total Assets 115.6m) |
| C: -0.68 (EBIT TTM -80.6m / Avg Total Assets 117.9m) |
| D: 6.19 (Book Value of Equity 99.5m / Total Liabilities 16.1m) |
| Altman-Z'' = -7.00 = D |
| DSRI: 3.0 (Receivables 122k/15.0k, Revenue 1.19m/2.50m) |
| GMI: 1.00 (fallback, negative margins) |
| AQI: 0.81 (AQ_t 0.03 / AQ_t-1 0.04) |
| SGI: 0.47 (Revenue 1.19m / 2.50m) |
| TATA: -0.16 (NI -80.1m - CFO -61.1m) / TA 115.6m) |
| Beneish M = -1.89 (Cap -4..+1) = B |
As of November 02, 2026, the stock is trading at USD 52.24 with a total of 466,045 shares traded. Over the past week, the price has changed by -1.47%, over one month by +2.65%, over three months by +49.09% and over the past year by +209.20%.
Current recommended Stop Loss: 44.90 (which is 14.1% or 2.4 ATR below the current price).
Pulse Biosciences has received a consensus analysts rating of 4.83. Therefore, it is recommended to buy PLSE.
- StrongBuy: 5
- Buy: 1
- Hold: 0
- Sell: 0
- StrongSell: 0
| Analysts Target Price | 62.3 | 19.3% |
P/S = 3169.4924
P/B = 38.0053
Revenue TTM = 1.19m USD
EBIT TTM = -80.6m USD
EBITDA TTM = -79.6m USD
Long Term Debt = 5.09m USD (estimated: total debt 6.77m - short term 1.69m)
Short Term Debt = 1.69m USD (from shortTermDebt, last quarter)
Debt = 6.77m USD (from shortLongTermDebtTotal, last quarter) (leases 6.77m already included)
Net Debt = -94.8m USD (calculated: Debt 6.77m - CCE 101.6m)
Enterprise Value = 3.66b USD (3.76b + Debt 6.77m - CCE 101.6m)
Interest Coverage Ratio = unknown (Ebit TTM -80.6m / Interest Expense TTM 0.0)
EV/FCF = -59.64x (Enterprise Value 3.66b / FCF TTM -61.4m)
FCF Yield = -1.68% (FCF TTM -61.4m / Enterprise Value 3.66b)
FCF Margin = -5.18k% (FCF TTM -61.4m / Revenue TTM 1.19m)
Net Margin = -6.76k% (Net Income TTM -80.1m / Revenue TTM 1.19m)
Gross Margin = -21.60% ((Revenue TTM 1.19m - Cost of Revenue TTM 1.44m) / Revenue TTM)
Gross Margin QoQ = 37.10% (prev 7.73%)
Tobins Q-Ratio = 31.68 (Enterprise Value 3.66b / Total Assets 115.6m)
Interest Expense / Debt = 0.0% (Interest Expense 0.0 / Debt 6.77m)
Taxrate = 21.0% (US federal default 21%)
NOPAT = -63.7m (EBIT -80.6m * (1 - 21.00%)) [loss with tax shield]
Current Ratio = 9.63 (Total Current Assets 105.7m / Total Current Liabilities 11.0m)
Debt / Equity = 0.07 (Debt 6.77m / totalStockholderEquity, last quarter 99.5m)
Debt / EBITDA = 1.19 (negative EBITDA) (Net Debt -94.8m / EBITDA -79.6m)
Debt / FCF = 1.55 (negative FCF - burning cash) (Net Debt -94.8m / FCF TTM -61.4m)
Total Stockholder Equity = 84.8m (last 4 quarters mean from totalStockholderEquity)
RoA = -67.90% (Net Income -80.1m / Total Assets 115.6m)
RoE = -94.42% (Net Income TTM -80.1m / Total Stockholder Equity 84.8m)
RoCE = -89.71% (EBIT -80.6m / Capital Employed (Equity 84.8m + L.T.Debt 5.09m))
RoIC = -59.97% (negative operating profit) (NOPAT -63.7m / Invested Capital 106.2m)
WACC = 7.62% (E(3.76b)/V(3.76b) * Re(7.63%) + D(6.77m)/V(3.76b) * Rd(0.0%) * (1-Tc(0.21)))
Discount Rate = 7.63% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: 90.46 | Cagr: 10.59%
[DCF] Fair Price = unknown (Cash Flow -61.4m)
EPS Correlation: N/A | EPS CAGR: N/A | SUE: -1.34 | # QB: -1
Revenue Correlation: N/A | Revenue CAGR: N/A | SUE: -0.53 | # QB: 0
EPS current Quarter (2026-09-30): EPS=-0.29 | Chg30d=+0.86% | Revisions=-25% | Analysts=4
EPS current Year (2026-12-31): EPS=-1.11 | Chg30d=+0.52% | Revisions=+25% | GrowthEPS=-46.8% | GrowthRev=+480.7%
EPS next Year (2027-12-31): EPS=-1.17 | Chg30d=-1.45% | Revisions=+25% | GrowthEPS=-5.6% | GrowthRev=+178.0%
[Analyst] Revisions Ratio: +17% (up=2, down=1)